<?xml version='1.0' encoding='utf-8'?>
<document id="24002148"><sentence text="Safety and pharmacokinetics of efinaconazole 10% solution in healthy volunteers and patients with severe onychomycosis."><entity charOffset="31-44" id="DDI-PubMed.24002148.s1.e0" text="efinaconazole" /></sentence><sentence text="To characterize the systemic exposure and pharmacokinetics of efinaconazole 10% solution and assess the potential for drug-drug interaction (DDI) in human volunteers and onychomycosis patients following topical administration"><entity charOffset="62-75" id="DDI-PubMed.24002148.s2.e0" text="efinaconazole" /></sentence><sentence text="" /><sentence text="Two single-center, open-label studies in healthy volunteers and severe onychomycosis patients" /><sentence text=" Efinaconazole 10% solution was applied topically to all 10 toenails (0"><entity charOffset="1-14" id="DDI-PubMed.24002148.s5.e0" text="Efinaconazole" /></sentence><sentence text="42 mL total daily dose volume); administered as single and then 7 daily doses to 10 healthy volunteers, and once daily for 28 days to 19 severe onychomycosis patients" /><sentence text=" Plasma concentrations of efinaconazole and its major metabolite H3 were determined by LC-MS-MS at multiple timepoints"><entity charOffset="26-39" id="DDI-PubMed.24002148.s7.e0" text="efinaconazole" /></sentence><sentence text=" Safety evaluations were carried out throughout both studies" /><sentence text="" /><sentence text="The mean peak plasma concentrations (Cmax) of efinaconazole and H3 were 0"><entity charOffset="46-59" id="DDI-PubMed.24002148.s10.e0" text="efinaconazole" /></sentence><sentence text="54 and 1" /><sentence text="63 ng/mL, respectively, in healthy volunteers; and 0" /><sentence text="67 and 2" /><sentence text="36 ng/mL, respectively, in patients" /><sentence text=" Both parent drug and metabolite accumulated following repeat dosing, and reached steady state in plasma by 14 days" /><sentence text=" Efinaconazole was well tolerated in both studies; no drug-related adverse events were reported"><entity charOffset="1-14" id="DDI-PubMed.24002148.s16.e0" text="Efinaconazole" /></sentence><sentence text="" /><sentence text="Efinaconazole 10% solution resulted in very low systemic exposures to efinaconazole and H3 when applied topically at maximum use conditions to healthy volunteer and onychomycosis patients' toenails"><entity charOffset="0-13" id="DDI-PubMed.24002148.s18.e0" text="Efinaconazole" /><entity charOffset="70-83" id="DDI-PubMed.24002148.s18.e1" text="efinaconazole" /><pair ddi="false" e1="DDI-PubMed.24002148.s18.e0" e2="DDI-PubMed.24002148.s18.e0" /><pair ddi="false" e1="DDI-PubMed.24002148.s18.e0" e2="DDI-PubMed.24002148.s18.e1" /></sentence><sentence text=" Efinaconazole is a CYP inhibitor like other azole antifungals, and its lowest ki is 91 ng/mL for CYP2C9, a &gt;130-fold higher concentration than the mean steady state Cmax observed in patients"><entity charOffset="1-14" id="DDI-PubMed.24002148.s19.e0" text="Efinaconazole" /><entity charOffset="45-50" id="DDI-PubMed.24002148.s19.e1" text="azole" /><entity charOffset="9-13" id="DDI-PubMed.24002148.s19.e2" text="azole" /><pair ddi="false" e1="DDI-PubMed.24002148.s19.e0" e2="DDI-PubMed.24002148.s19.e0" /><pair ddi="false" e1="DDI-PubMed.24002148.s19.e0" e2="DDI-PubMed.24002148.s19.e2" /><pair ddi="false" e1="DDI-PubMed.24002148.s19.e0" e2="DDI-PubMed.24002148.s19.e1" /><pair ddi="false" e1="DDI-PubMed.24002148.s19.e2" e2="DDI-PubMed.24002148.s19.e2" /><pair ddi="false" e1="DDI-PubMed.24002148.s19.e2" e2="DDI-PubMed.24002148.s19.e1" /></sentence><sentence text=" The Cmax/ki ratio was 0" /><sentence text="007, well below the threshold for clinical DDI evaluation as recommended in regulatory guidances, thereby suggesting efinaconazole 10% solution has remote potential for drug-drug interactions"><entity charOffset="117-130" id="DDI-PubMed.24002148.s21.e0" text="efinaconazole" /><entity charOffset="125-137" id="DDI-PubMed.24002148.s21.e1" text="azole" /><pair ddi="false" e1="DDI-PubMed.24002148.s21.e0" e2="DDI-PubMed.24002148.s21.e0" /><pair ddi="false" e1="DDI-PubMed.24002148.s21.e0" e2="DDI-PubMed.24002148.s21.e1" /></sentence><sentence text="" /></document>